Kornimate/medical-research-clean huggingface dataset:
immunomonitoring of breast cancer patients during systemic treatment

Conditions: Breast Cancer

Summary: this study aims to constitute a most complete biological collection for patients treated for localized or metastatic breast cancer (in different cohorts depending on the type of systemic treatment received), in order to describe the basal immune response of patients treated for a breast cancer according to the stage of the disease, but above all to study how the different systemic treatments used in the management of breast cancer modulate this immune response.

the main objective of this study is to describe, depending on the type of systemic treatment received, the blood immune response before treatment and its evolution under treatment.

Eligibility criteria:
inclusion criteria: 1. woman aged between 18 and 85. 2. patient with histologically proven infiltrating breast cancer. 3. triple negative breast cancer or rh + / her2- (or and rp \<10% and her2 negative (0 or 1+ in ihc or 2+ in ihc and fish negative) 4. patient receiving treatment corresponding to one of these cohorts: * in a metastatic situation with establishment of treatment with paclitaxel regardless of the treatment line * in a metastatic situation with establishment of treatment with epirubicin - cyclophosphamide (ec) regardless of the treatment line * in a metastatic situation with establishment of treatment with eribulin regardless of the line of treatment * in a 1st line metastatic situation with initiation of treatment with palbociclib or abemaciclib, or ribociclib in combination with hormone therapy (aromatase inhibitor) 5. patient who signed the informed consent for the study. 6. patient fit and able to adhere to protocol for the duration of the study, including visits, scheduled specimens and follow-up. 7. patient affiliated to the social security system. exclusion criteria: 1. patient unable to understand, read and / or sign informed consent. 2. presence of cerebral or meningeal metastasis 3. current or previous use of an immunosuppressive drug in the 14 days preceding inclusion (except intranasal corticosteroids, systemic corticosteroids at physiological doses not exceeding 10 mg per day of prednisone or its equivalent, corticosteroids for antiemetic purposes, corticosteroids used as premedication for hypersensitivity reactions (injected ct scan, taxanes, etc.) 4. patient participating in another research that may modify the systemic treatment administered in the framework of the cohort in which she will be included. 5. pregnant or breastfeeding woman. 6. hiv and / or hbv and / or hcv serology positive. 7. life expectancy estimated at less than 3 months. 8. patient's refusal. 9. person benefiting from a protection system for adults (including tutorship and curatorship). 10. inability to undergo medical monitoring of the trial for geographical, social or psychological reasons.

Keywords: immune response blood samples
delta primary care provider (pcp) survey on asthma management

Conditions: Asthma

Summary: the proposed study will utilize a survey format to examine the attitudes, perceptions, and practices of primary care providers in the delta region of arkansas.

study design. primary care providers will be sent a providers packet to include a cover letter explaining the survey and its purpose as well as a 2-part questionnaire that includes nine selected short patient vignettes and a questionnaire regarding their personal and practice characteristics. study population. individuals who receive the survey will be the primary care provider identified by study participants enrolled in our ongoing study entitled, "asthma in the delta region of arkansas: characterization of disease and impact of environmental factors" (aria#53054). we will send the survey to all identified practitioners in lee, phillips, desha, chicot, st. francis, and surrounding counties. future studies will include primary care providers from other arkansas delta counties pending funding. inclusion/exclusion criteria. we will send the survey to all identified practitioners in lee, phillips, desha, chicot, st. francis, and surrounding counties. future studies will include primary care providers from other arkansas delta counties pending funding. instruments. delta primary care provider survey. the self administered survey examines the attitudes, perceptions and practices of primary care providers. the 2-part questionnaire includes nine selected short patient vignettes and a questionnaire regarding the providers personal and practice characteristics.

Eligibility criteria:
inclusion criteria: * we will send the survey to all identified practitioners in lee, phillips, desha, chicot, st. francis, and surrounding counties. * future studies will include primary care providers from other arkansas delta counties pending funding. exclusion criteria: * none.

Keywords: characteristics of medical practices practitioners providing care to children with asthma medically underserved and impoverished arkansas delta region characteristics of medical practices and practitioners disadvantaged populations
omega-3 fatty acids in bariatric gastric bypass surgery: effect on liver volume, immune response and erythrocyte function

Conditions: Morbid Obesity

Summary: gastric bypass surgery is the gold standard in bariatric surgery and is a successful method to reduce weight in morbidly obese subjects. patients qualified for gastric bypass surgery are routinely pre-treated with a low calorie diet in order to reduce liver volume and to facilitate the approach of the gastro-oesophageal junction. pre-treatment with omega-3 fatty acids has similar effects on liver volume, but a prospective comparison of both treatments has not been performed yet. morbidly obese patients respond differently to surgical stress, due to a number of factors. first, obesity is associated with a low-grade inflammatory state induced by an increased amount of macrophages in adipose tissue. this state is associated with higher levels of pro-inflammatory cytokines in serum and with a less adequate immune response to infections. second, obesity is associated with an altered cortisol metabolism possibly related to adrenal insufficiency. this could play an important role in the altered response to surgical stress and postoperative complications in obese subjects. third, obesity is associated with altered erythrocyte function, including decreased erythrocyte deformability and increased aggregation, factors contributing to an impaired microcirculation. this study has a number of different aims. first, we will compare pre-treatment with the standard low calorie diet with omega-3 fatty acids on liver volume in patients qualified for gastric bypass surgery because of morbid obesity. second, we will investigate the effect of omega-3 fatty acids on immune function, the low-inflammatory state of adipose tissue, the stress response of obese subjects before and erythrocyte function. third, we will investigate the effect of gastric bypass surgery by comparing values before surgery with values on the first postoperative day and 6 months after surgery regarding to immunological parameters, stress response and erythrocyte function.


Eligibility criteria:
inclusion criteria: * females undergoing laparoscopic gastric bypass surgery because of morbid obesity * age between 18 and 65 years * able to fit in the mri * written informed consent exclusion criteria: * pregnancy * diabetes mellitus type 1 * current history of inflammatory, infectious or malignant disease * daily use of anti-inflammatory drugs * contra-indications for mri imaging * contra-indications for the use of omega-3 fatty acids
laparoscopic cholecystectomy with retro-infundibular approach

Conditions: Gallstones

Summary: aimed to evaluate laparoscopic cholecystectomy by retro-infundibular (ri) approach compared to standard laparoscopic cholecystectomy (slc) in difficult cases with scarred chole-cystohepatic (calot's) triangle.

this study is a prospective cohort study, conducted in minia university hospital and minia insurance hospital in the period from july 2013 to january 2016, where 597 patients with gallstones were admitted for laparoscopic cholecystectomy and were done by the same surgeon. based on the preoperative scoring system to predict the degree of difficulty in laparoscopic cholecystectomy, patients that had the score \> 6 and were fit for laparoscopic surgery were included in the study. only 125 met these criteria and agreed to share in the study and gave their informed consent. 60 patients were operated by slc (group 1).this included the classic dissection of calot's triangle to achieve the cvs, with separate clipping and division of cystic duct and artery. while, 65 patients were operated by laparoscopic cholecystectomy using ri approach (group 2). this included separation of the lower third of gb from its bed down to its pedicle (artery and duct) with mass ligation of both. operative procedure of by ri approach: the site of trocars was the same as for the standard cholecystectomy. after dissection of adhesion masking the gb, if present, to reach the hartmann pouch, at this point calot's triangle usually was scarred and frozen, the surgeon never tried to dissect it and instead the surgeon continued as follow : 1. de-shouldering of gb: by incising the serosal covering on either side of the infundibulum and lower part of the body. 2. this followed by dissection and separation of the lower third of gb body from its bed, using suction-irrigation probe or hook dissector. dissection continued downward till the gb pedicle (duct and artery). 3. mass ligation of cystic artery and duct, using intracorporeal note by vicryl number 1 suture. 4. then the surgeon cut above the ligature using diathermy on scissor or ultrasound sealing device. during this step the cut end of the gb was grasped by forceps trying to prevent spillage of its content, if happened, stones were collected in a bag and extracted. 5. then gb was dissected from its bed as usual and extracted in a bag. in cases where the gb was hugely distended, it was aspirated firstly to facilitate its grasping. also in cases of mirizzi syndrome the gb was opened direct on the stone to remove it, to facilitate grasping of gb then we continued as described above

Eligibility criteria:
inclusion criteria: * patient with gallstones * score difficulty according to gupta et al 2013 \> 6 * patient fit for laparoscopic surgery exclusion criteria: * score difficulty according to gupta et al 2013 \> 6 * patient unfit for laparoscopic surgery * refusal to share in the study
the effect of the mobile application developed for home care of preterm

Conditions: Mother; Premature; Education; Home Care; Mobile Application

Summary: mobile application will be developed to support the post-discharge home care of mothers of premature babies. with the developed mobile application, the effect of the education given to the mothers on the knowledge and skills of infant care, mother-infant attachment, and the mother's self-efficacy will be evaluated.

this research aims to examine the effect of the mobile application developed for the home care of the babies of the mothers of premature babies on their baby care knowledge and skills, mother-infant attachment and mother self-efficacy. a mobile application will be developed to support mothers who care for their premature babies at home after discharge. the application will be installed on the phones of mothers whose babies are discharged from the neonatal intensive care unit. after the babies are discharged, mothers will be trained at home with a mobile application. maternal self-efficacy and mother-infant supplementation will be measured when infants admitted the nicu and one month after discharge the nicu.

Eligibility criteria:
inclusion criteria: for mothers; * being over the age of 18, * having a premature baby * at least primary school graduate, * smart mobile app can be installed have a phone, * being able to understand and speak turkish, * residing in ankara for babies; * 32-37 weeks of gestation of the baby (middle and borderline premature) * baby in neonatal intensive care unit to stay * not having undergone a surgical operation, * absence of physical anomalies exclusion criteria: for mothers; * diagnosed with postpartum depression * unwillingness to participate in the study for babies; - very small preterm (born below 28 weeks of gestation) and small preterm (between 28 and 31 weeks of gestation)

Keywords: mothers, premature, mobile application, education, home care
a clinical trial to evaluate the recombinant human type5 adenovirus vector based ebola virus disease vaccine

Conditions: Ebola Disease

Summary: a single-center, randomized, blind, phase ii clinical trial to evaluate the safety and immunogenicity of the adenovirus type 5 vector based ebola virus disease vaccine (ad5-ebov) in healthy adults aged between 18 and 50 years in sierra leone.


Eligibility criteria:
inclusion criteria: * aged between 18 and 50 years * able to understand the content of informed consent and signed the informed consent * able and willing to complete all the secluded study process during the whole study follow-up period (about 6 months). * negative in hiv diagnostic blood test on day of enrollment * axillary temperature ≤37.0°c on the day of enrollment * non-pregnant females with a negative result in the urine pregnancy test on day of enrollment * general good health as established by medical history and physical examination. exclusion criteria: * infected by ebola virus (inquiry) * vaccination with other ebola vaccine (inquiry) * hiv infection or other serious immunodeficiency disease (inquiry) * allergic history of any vaccination or drugs, or allergic to any ingredient of the ad5-ebov, such as mannitol * family history of brain or mental disease * woman who is pregnant or breast-feeding * any acute fever disease or infections in last 7 days * major congenital defects or not well-controlled chronic illness * asplenia or functional asplenia * platelet disorder or other bleeding disorder * faint at the sight of blood or needles. * prior administration of immunodepressant or corticosteroids, antianaphylaxis treatment, cytotoxic treatment in last 6 months * prior administration of other research medicines in last 1 month * prior administration of attenuated vaccine(s) in the last one month * prior administration of inactivated vaccine(s) in the last 14 days * any condition that in the opinion of the investigators may interfere with the participants' compliance or evaluation of study objectives
multiple myeloma/chronic lymphocytic leukemia coach rct

Conditions: Multiple Myeloma; Chronic Lymphocytic Leukemia

Summary: the purpose of this study is to test the effectiveness of evidence-informed mobile apps, myeloma coach and cll coach. these apps have been developed to help manage the physical and emotional symptoms experienced by multiple myeloma and chronic lymphocytic leukemia survivors. this study hopes to determine if a mobile app is a useful tool to help people manage commonly reported symptoms related to multiple myeloma (mm) and chronic lymphocytic leukemia (cll).


Eligibility criteria:
inclusion criteria: * be at least 18 years of age; * be a resident of the united states of america; * be able to read and write english * consistent access to the internet via a smartphone, tablet or computer * have a diagnosis of multiple myeloma or chronic lymphocytic leukemia

Keywords: mm cll
individual patient expanded access for acellular tissue engineered vessel (atev) / human acellular vessel (hav)

Conditions: Vascular Diseases; Vascular System Injuries; End Stage Renal Disease on Dialysis

Summary: individual patient expanded access requests may be considered for patients who have no other treatment options and are not eligible for an atev clinical study

procedure for requesting expanded access: the treating physician requesting expanded access must contact humacyte directly with the basis for the request. please include your contact information so that humacyte may follow up with you directly. general criteria: we will evaluate and respond to each expanded-access request that we receive on a case-by-case basis. humacyte will consider the nature of the request, the patient's health, the available medical and scientific information about the investigational product, the balance of risk and potential benefit to the patient, the availability of investigational product, and the potential regulatory impact. anticipated timing: if you contact humacyte as described above, humacyte anticipates that we will acknowledge receipt within ten (10) business days or less.

Eligibility criteria:
inclusion criteria: - exclusion criteria: -
hydroxychloroquine in untreated b-cll patients

Conditions: B-Cell Chronic Lymphocytic Leukemia

Summary: eligible cll patients who sign an informed consent will be started on hydroxychloroquine 400mg po daily for up to one year. they will be monitored for disease status as well as adverse reactions after two weeks and then every 4 weeks. ophthalmologic exams is required at baseline and every 6 months or sooner if the patient develops any visual disturbances.

this is a single-center, open-label, single arm phase 2 study evaluating the feasibility, and efficacy of treating cll subjects with hydroxychloroquine. the study schema and schedule of events are as follows: prior to beginning hydroxychloroquine: * blood samples to be taken. * baseline tests confirming diagnosis of cll as defined above (if not already obtained in records) * physical exam performed * either six months prior or 4 weeks within starting hcq ophthalmologic exam documented * days 1-365 subject takes hydroxychloroquine 400mg/day * at 2 weeks: cbc and chemistry * every 4 weeks: cbc, chemistry, history (including the inquiry about the presence or absence of visual symptoms) and physical exam. * starting at 4 weeks: blood samples taken for laboratory companion studies taken at office visit every 8 weeks. * at 6 months (+ or - 30 days): subject will have follow up ophthalmologic exam). this will also be done in the presence of any visual/ocular symptoms. all subjects must meet the selection criteria for registration in this study. all subjects must have a peripheral blood sample submitted. it is estimated that approximately 70 subjects will be screened. the anticipated accrual period is 12 months.

Eligibility criteria:
inclusion criteria: * flow cytometry confirmed b-cll * no prior chemotherapy or immunotherapy * performance status 0-2 * age \> 18 years old * if childbearing age, woman you must be willing to use birth control for length of hydroxychloroquine use * must have capacity to consent for study and sign consent form * asymptomatic cll not requiring treatment at time of study entry exclusion criteria: * pregnancy * significant optic nerve pathology as documented by an opthalmologic exam * hypersensitivity to 4-aminoquinoline compound * patients taking cardiac glycosides and cyclosporine

Keywords: untreated
future of the older patients after intensive care unit

Conditions: Intensive Care Unit Syndrome

Summary: estimate the future six months after the admission in an intensive care unit of the patients of 85 and more years old in terms of autonomy.

the diverse studies published on the future of the elderly hospitalized in resuscitation place the limit very low, between 65 and 80 years. the feeling of a very bad forecast at these extreme ages pulls nevertheless a filter in the admission in icu which has this day no scientific justification. the knowledge of the evolution after the hospitalization of these older patients can help to make certain decisions concerning as well the admission of these patients in icu as the realization of invasive treatments. after informal interrogation of numerous intensivists, it seems to take shape a bar around 85 years beyond which the forecast would be worse without more proof what consolidated the choice of this limit. the reserved scores were already used in similar studies (simplified ald). primary purpose : * describe the survival and the evolution of the quality of life after a stay in resuscitation for very old patients. * the quality of life will be studied through a score of autonomy: the simplified ald score. the population will be described in general then by age bracket (more or less of 90 years old), according to the length of stay in icu, the heavy treatments (artificial ventilation, renal replacement therapy) practiced, the initial gravity (score igs 2). the impact of possible decisions of limitation or stop of therapeutic activates will also be taken into account.

Eligibility criteria:
inclusion criteria: * all patients over 85 years old staying in intensive car units exclusion criteria: * knaus d * no possibly of call (phone) 6 months after icu admission * patients who do not speak french * patients do not accept the participation

Keywords: intensive care elderly autonomy future older patients intensive care unit
docetaxel and immunotherapy prior to prostatectomy for high-risk prostate cancer

Conditions: Prostate Cancer

Summary: the purpose of this study is to find out what effects, good and bad, the combination of docetaxel with cg1940/cg8711 (immunotherapy drugs) have on destroying prostate cancer before removal the prostate (prostatectomy).


Eligibility criteria:
inclusion criteria: * patients must have clinical stage 1-3 disease and no radiographic evidence of metastatic disease * nomogram prediction: patients must have a kattan nomogram predicted probability of being free from biochemical progression at 5 years after surgery of \<60%. exclusion criteria: * concurrent or prior treatment with radiation, cytotoxic or biologic therapy for prostate cancer, prior hormonal therapy (except finasteride or dutasteride for obstructive voiding symptoms) * male patients unwilling to use effective means of contraception are excluded. contraception should be continued for 3 months after treatment. * prior malignancy will not exclude the patient. (patients can not have active cancer or be undergoing active treatment). the principal investigator will make final decision regarding eligibility since the end point is pathological complete response.